INPLASY202250048

Adverse events and tolerability of combined durvalumab and tremelimumab versus durvalumab alone in solid cancers: a systematic reviewand meta-analysis

Keywords: Durvalumab; Tremelimumab; Side effects; cancer.

Download PDF - 202250048

Review Status: Completed but not published